(19)
(11) EP 2 137 192 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
11.06.2014 Bulletin 2014/24

(45) Mention of the grant of the patent:
19.02.2014 Bulletin 2014/08

(21) Application number: 08735211.8

(22) Date of filing: 14.04.2008
(51) International Patent Classification (IPC): 
C07D 491/10(2006.01)
A61P 25/00(2006.01)
 A61K 31/4355(2006.01)
(86) International application number:
PCT/EP2008/002929
(87) International publication number:
WO 2009/127218 (22.10.2009 Gazette 2009/43)

(54)

Derivatives of galantamine as pro-drugs for the treatment of human brain diseases

Galantaminderivate als Prodrug-Verbindungen zur Behandlung humaner Hirnerkrankungen

Dérivés de galantamine comme promédicaments pour le traitement de maladies du cerveau humain

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

(43) Date of publication of application:
30.12.2009 Bulletin 2009/53

(73) Proprietor: Neurodyn Life Sciences Inc.
Charlottetown, P.E.I., C1A 4P3 (CA)

(72) Inventor:
  • MAELICKE, Alfred
    55268 Nieder-Olm (DE)

(74) Representative: Boeckh, Tobias et al
Hertin und Partner Rechts- und Patentanwälte Kurfürstendamm 54/55
10707 Berlin
10707 Berlin (DE)


(56) References cited: : 
EP-A- 1 777 222
 WO-A-99/21561
   
  • HAN S-Y ET AL: "SYNTHESIS AND BIOLOGICAL ACTIVITY OF GALANTHAMINE DERIVATIVES AS ACETYLCHOLINESTERASE (ACHE) INHIBITORS" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, ELSEVIER SCIENCE, GB, vol. 1, no. 11, 1 January 1991 (1991-01-01), page 579/580, XP001181208 ISSN: 0960-894X
 
Remarks:
The file contains technical information submitted after the application was filed and not included in this specification
 
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).